Healthcare costs and health outcomes analysis of neoadjuvant Trastuzumab therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer
{{output}}
Background: Globally, the incidence of breast cancer continues to rise; however, mortality rates are declining due to the growing effectiveness of targeted therapies and treatments. Overexpression of human epidermal growth factor... ...
